%0 Journal Article %A Adel Bougatef %A Guadalupe Martinez %A Derrick Watson %A Shannon Hardy %A Ashley Phillips %A Rodney Gray %T High Flow Nasal Therapy (HFNT) in Pediatric patients at the Home %D 2020 %R 10.1183/13993003.congress-2020.3416 %J European Respiratory Journal %P 3416 %V 56 %N suppl 64 %X Background: HFNT is a frequently used modality for the hospitalized pediatric and neonatal populations, their length of stay at the hospital for technology-dependent raison remains very high. The use of HFNT in the home is challenging. The Trilogy 100 Ventilator (Phillips), heated and humidified breathing circuit in conjunction with the RAM Cannula (RC, Neotech) has been used to address these challenges.Methods: A retrospective medical records review of 30 pediatric patients placed on HFNT in the home between May 2015 & November 2017 was completed. Prior to his implementation in the home, a bench evaluation of the inter-relationships among set CPAP level, delivered flow, and RC size was performed using Michigan Instrument 5601i lung simulator, and TSI flow meter 4000 series. The algorithm was than developed and instituted. Flow is generated via set CPAP levels at the Trilogy 100, three sizes of RC (preemie-newborn-infant) was used, and flow output (L/min) was measured, results are illustrated in the table below.Results: 30 pediatric patients with chronic respiratory illness were studied. Mean gestational age was 34.2 ± 5.5 weeks, 16 are male and 14 female, 57% have chronic lung disease, 43% have neuromuscular disorder, 60% are oxygen dependent. The median age at HFNT initiation was 10 months (2-75). CPAP levels was 7.0 ± 3.0 cmH2O. HFNT failed in 6 patients (20%), the median duration of HFNT was 9 weeks (1-44).Conclusion: Successful implementation of HFNT at the home, using our developed algorithm, in pediatric patients with chronic respiratory illness, gives option for early discharge of hospitalized technology-dependent patients. View this table:FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3416.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U